Vaneltix Pharma, Inc.

Hyloris remains on-track to broaden its product pipeline to its target of 30 product candidates and marketed products by 2024, delivering a confident-half year update in the face of some pushback fro

Belgian value-added medicines firm Hyloris Pharmaceuticals SA has successfully raised €15.0m ($16.2m) from investors “new and existing, local and international,” through an equity offering by means

Belgian value-added medicines company Hyloris Pharmaceuticals SA has outlined an ambitious growth strategy while announcing its financial and operational results for the full-year ending 31 December